Company Overview and News

7
Is the Options Market Predicting a Spike in Calumet Specialty (CLMT) Stock?

2018-10-05 zacks
Investors in Calumet Specialty Products Partners, L.P. (CLMT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $3.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CLMT WBA LMAT YY

14
Ferrellgas Partners (FGP) Posts Wider-Than-Expected Q4 Loss

2018-09-28 zacks
Ferrellgas Partners LP (FGP - Free Report) reported fourth-quarter fiscal 2018 adjusted loss of 63 cents per unit, wider than the Zacks Consensus Estimate loss of 41 cents.
CLMT GPN SUN TRGP FGP

63
Weekly Insider Trading, September 23

2018-09-24 seekingalpha - 2
Odonate Therapeutics - CEO Kevin Tang continues to make huge open market purchases awaiting phase III results in 2020.
CWH ODT CLMT AZN HRTX

 
CLMT / Calumet Specialty Products Partners, L.P. S-8

2018-08-09 sec.gov
Document As Filed with the Securities and Exchange Commission on August 9, 2018
CLMT

 
Calumet Specialty Products Partners, L.P. 2018 Q2 - Results - Earnings Call Slides

2018-08-09 seekingalpha
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with their 2018 Q2 earnings call.
CLMT

1
Strategies For The Bursting Bond Bubble

2018-07-11 seekingalpha
This year’s increased stock market volatility and sharp declines in the emerging markets are the result of rising interest rates. If interest rates revert to the normal 2007 pre-financial crisis levels, a process not even halfway complete, the potential for significant declines in equity, bond and real estate markets becomes a serious and present risk. This letter will address ways to help preserve your wealth if rising interest rates trigger significant market declines.
AMID CLMT SXE

 
Calumet Specialty Products Heading Dramatically Higher

2018-07-10 seekingalpha
Calumet is in the middle of an extraordinary turnaround, which has been recently masked by the effects of Hurricane Harvey and a botched computer (ERP) implementation.
CLMT MS

 
Husky awaits explosion investigation results before restarting asphalt refinery

2018-07-04 cbc.ca
Two months after fire and explosions ripped through its recently purchased asphalt refinery in Superior, Wis., Husky Energy Inc. says it still doesn't know when it will be able to restart the facility.
HSE CLMT HUSKF

57
High-Yield Investment Strategy Fails

2018-07-03 seekingalpha - 1
The performance of 59 securities, which were selected by SA contributors for their high-yield portfolios in 2014, are identified and analyzed for the period May 2014 to July 2018.
AIY AINV ARI PCI NYMTO HTF KAP OSLE NYMTP KCAP FGB AI CMO TWO SDRL HTFA AGNC AIW SLRA RSO WMC AIC AIB TCRD PSEC NMFC CYS AIF TSLF MCX SCQ XAN PBB SCA MCQ HRZN CHW OXLCO MCV OXLCN STWD.WI MITT SCM HTGZ SLRC BIT MCC TCRX ARCC GBDC CLMT MFO DX NLY TCPC TCRZ HTGX OXLC HTGY ARU OCSL EFC MFA NYMT HTGC STWD

12
Calumet Specialty (CLMT) Presents At BMO Capital Markets Chemicals Conference - Slideshow

2018-06-26 seekingalpha
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with this event.
CLMT

17
Ferrellgas Partners (FGP) Lags Q3 Earnings, Sales Estimates

2018-06-07 zacks
Ferrellgas Partners LP (FGP - Free Report) reported third-quarter fiscal 2018 adjusted earnings of 18 cents per unit, missing the Zacks Consensus Estimate of 26 cents by 30.8%. Total Revenues In the reported quarter, Ferrellgas Partners’ total revenues were $515.8 million, missing the Zacks Consensus Estimate of $621 million by 17%. The top line also declined 4.1% from $538 million in the prior-year quarter.
SRLP CLMT SUN FGP

12
Calumet Specialty Products Partners (CLMT) Presents At Bank of America Merrill Lynch Energy Credit Conference - Slideshow

2018-06-06 seekingalpha
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with this event.
CLMT

27
Top MLP Gainers in the Week Ending June 1

2018-06-06 marketrealist
Calumet Specialty Products Partners (CLMT), an MLP involved in the production of specialty fuels and other refined products, was the top MLP gainer in the week ending June 1. Calumet Specialty Products Partners rallied 23.9%. Last week, the gains could have been due to strong refined products demand during Memorial Day weekend and the start of the summer driving season. Calumet Specialty Products Partners has traded in the green for 2018 following last week’s rally.
NGL LGCYP LGCYO CLMT ENLK ENLC CEQP NSH LGCY CVRR ENBL NS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CLMT / Calumet Specialty Products Partners, L.P. on message board site Silicon Investor.

Claremont Technology Group (CLMT) Claremont Technology Group (CLMT) Claremont Technology Group (CLMT)
CUSIP: 131476103